This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GenMark Diagnostics Reports Second Quarter 2012 Results

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding continued growth in sales of our diagnostic tests, the expansion of our diagnostic test menu, the development and functionality of our products and the continued development of our technology, are all subject to risks and uncertainties that could cause our actual performance, operating results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, our ability to successfully commercialize our products, inherent risk and uncertainty in the protection of intellectual property rights, ability to maintain gross margins, regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

GenMark Diagnostics, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except par value)
 
 
As of As of
June 30, 2012 December 31, 2011
Current assets
Cash and cash equivalents $ 64,219 $ 25,320
Short- term investments 5,000
Accounts receivable—net of allowance of $80 and $98 1,286 1,098
Inventories 1,879 2,168
Other current assets 192   322  
 
Total current assets 67,576 33,908
Property and equipment—net 4,185 2,836
Intangible assets—net 1,672 1,362
Other long-term assets 102   80  
 
Total assets $ 73,535   $ 38,186  
 
Current liabilities
Accounts payable $ 1,570 $ 1,201
Accrued compensation 1,594 1,521
Current portion of long-term debt 1,016 1,000
Other current liabilities 2,551   2,659  
 
Total current liabilities 6,731 6,381
 
Long-term liabilities
Long-term debt, net of current portion 155 583
Other non-current liabilities 805   588  
 
Total liabilities 7,691   7,552  
 
Stockholders’ equity
Common stock, $0.0001 par value; 100,000 authorized; 32,724 and 20,478 issued and outstanding as of June 30, 2012 and December 31, 2011, respectively 3 2
Preferred stock, $0.0001 par value; 5,000 authorized, none issued
Additional paid-in capital 245,897 199,531
Accumulated deficit (179,620 ) (168,463 )
Accumulated other comprehensive loss (436 ) (436 )
 
Total stockholders’ equity 65,844   30,634  
 
Total liabilities and stockholders’ equity $ 73,535   $ 38,186  
 
GenMark Diagnostics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
     
Three Months ended June 30, Six months ended June 30,
2012   2011   2012   2011  
Revenue
Product revenue $ 3,562 $ 866 $ 5,682 $ 1,559
License and other revenue   50     35     89     100  
 
Total revenue 3,612 901 5,771 1,659
Cost of sales   2,165     1,294     3,853     2,795  
 
Gross profit (loss)   1,447     (393 )   1,918     (1,136 )
 
Operating expenses
Research and development 3,020 2,292 4,969 4,856
Sales and marketing 1,360 1,220 2,779 2,439
General and administrative   2,648     1,810     5,233     3,933  
 
Total operating expenses   7,028     5,322     12,981     11,228  
 
Loss from operations (5,581 ) (5,715 ) (11,063 ) (12,364 )
 
Other (expense) income, net   (9 )   147     (53 )   165  
 
Loss before income taxes (5,590 ) (5,568 ) (11,116 ) (12,199 )
Provision for income taxes   (10 )   (12 )   (41 )   (23 )
 
Net loss $ (5,600 ) $ (5,580 ) $ (11,157 ) $ (12,222 )
 
Net loss per share, basic and diluted $ (0.26 ) $ (0.39 ) $ (0.54 ) $ (0.93 )
Weighted average number of shares outstanding 21,163 14,366 20,623 13,076
 
Consolidated Statements of Comprehensive Loss For the Three and Six Months ended June 30, 2012 and 2011
Net loss $ (5,600 ) $ (5,580 ) $ (11,157 ) $ (12,222 )
Foreign currency translation adjustment   -     (64 )   -     (64 )
 
Comprehensive loss $ (5,600 ) $ (5,644 ) $ (11,157 ) $ (12,286 )
 
GenMark Diagnostics, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
   
 
Six Months ended June 30,
2012   2011  
Cash flows from operating activities
Net loss $ (11,157 ) $ (12,222 )
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization 576 622
Share-based compensation 1,033 1,227
Change in allowance for doubtful accounts (18 ) 72
Non-cash inventory adjustments (740 ) 123
Changes in operating assets and liabilities:
Accounts receivable (170 ) (34 )
Inventories 1,139 (398 )
Other current and long-term assets 108 1,673
Accounts payable 369 1,443
Accrued compensation 277 92
Other current and long-term liabilities   (162 ) (591 )
 
Net cash used in operating activities   (8,745 ) (7,993 )
 
Cash flows from investing activities
Proceeds from maturity of investments 5,000
Payments for intellectual property licenses (739 ) (365 )
Purchases of property and equipment   (1,529 ) (609 )
 
Net cash used in investing activities   2,732   (974 )
 
Cash flows from financing activities
Proceeds from the issuance of common stock 48,300 34,532
Costs incurred in conjunction with public offerings (2,919 ) (2,377 )
Proceeds of borrowings 2,000
Proceeds from stock option exercises 52
Principal repayments of borrowings   (521 )  
 
Net cash provided by financing activities   44,912   34,155  
 
Net increase (decrease) in cash and cash equivalents 38,899 25,188
Cash and cash equivalents—Beginning of period   25,320   18,329  
 
Cash and cash equivalents—End of period $ 64,219   $ 43,517  
 
Supplementary schedule of non-cash transactions:
Property and equipment purchased with capital lease $ 109 $
Transfer of systems from property and equipment into inventory 110 34
Property and equipment costs incurred but not paid incl. in accounts
payable and accrued liabilities 307 482
Offering costs incurred but not paid incl. in other current liabilities 303 416
 




3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,864.61 -63.59 -0.35%
S&P 500 2,083.39 -6.07 -0.29%
NASDAQ 4,926.4620 -12.8650 -0.26%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs